Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

This billing/coding guidance covers molecular assays used to diagnose cutaneous melanoma, including myPath®Melanoma and other assays. Use CPT 81479 for myPath tests before 2019-07-01 and CPT 0090U on/after 2019-07-01; use 81479 for other assays if no applicable CPT/PLA code exists, bill one unit and only one test per patient per melanocytic lesion, and include the appropriate DEX Z-Code identifier and ICD-10-CM diagnosis code in the specified claim fields.

"Molecular assays performed for the diagnosis of cutaneous melanoma (including myPath®Melanoma and other molecular assays) may be billed under this guidance."

Sign up to see full coverage criteria, indications, and limitations.